Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675023 · ClinicalTrials.gov registry record · Phase 1
Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
A Phase 1 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 603
- Enrollment target
NCT02675023 is a Phase 1 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 603 participants.
The verdict
NCT02675023, a Phase 1 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 603 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
Interventions
- BIOLOGICAL M923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675023
The ClinicalTrials.gov registry entry for NCT02675023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M923 is the first listed.
NCT02675023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675023 about?
NCT02675023 is a clinical study titled "Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects". This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
What is the current status of trial NCT02675023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 603 participants. The study started on 2016-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02675023?
The interventions under investigation include: M923 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02675023?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.